Canary in a Coal Mine (4.19.2024)
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read Article
BSR Guideline on Management of Sjogren’s Syndrome
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficent interventions for those affected with mucosal or systemic manifestations.
https://t.co/M5fQ8lyZBS https://t.co/30XpP3r4FV
Dr. John Cush @RheumNow( View Tweet )
Biopsy Results in Sjogren's Syndrome Save
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected SjD.
https://t.co/meJgf7dI8N https://t.co/zHg6SgiufS
Dr. John Cush @RheumNow( View Tweet )
BSR Guideline on Management of Sjogren’s Syndrome
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficent interventions for those affected with mucosal or systemic manifestations.
The British Society of Rheumatology has updated its 2017 guidelines, with wider
Read Article
Biopsy Results in Sjogren's Syndrome
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Researchers from the University Medical Center Groningen compared
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that RA patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
https://t.co/4dcackIe4S https://t.co/5VZ9I7r29F
Dr. John Cush @RheumNow( View Tweet )
Activity & Pain Tolerance (3.29.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including where you should sit in clinic and why you should worry about secondary Sjogren's in RA.
Read Article
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that rheumatoid arthritis (RA) patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
From a total of 5974 RA patients, there were 337 patients with concomitant SjD. All
Read Article
Naysayers & Disrupters (3.22.2024)
Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis.
Read Article
929 Sjogrens pts from 2 French cohorts subdivided into 3 Groups:
1. BALS: Hi B-cell activity, low Sxs (Dz activity worsened w/ time)
2. HSA: Hi systemic Dz
3. LSAHS: low systemic Dz, Hi Sxs
Lymphomas in 3-4% BALS & HSA
https://t.co/xI8qjLO8YQ https://t.co/Z2JBuKSUhi
Dr. John Cush @RheumNow( View Tweet )
Sniffles & Arthritis (3.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide....
No clear link between weather & MSK symptoms
J&J announced the results of Phase 2 DAHLIAS study of nipocalimab in Sjögren’s; w/ a signif reduction in clinESSDAI at week 24 vs placebo. Nipocalimab is an investigational anti-FcRn treatment being studied in RA, & myasthenia gravis https://t.co/mroLPx0BnH https://t.co/7IqlY1K6di
Dr. John Cush @RheumNow( View Tweet )
Best of 2023: Postural Orthostatic Tachycardia Syndrome Review
The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.
Read Article
ACR 2023 – Day 4 Report
The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations. Here’s a list of the late breakers; below, I provide commentary on the ones
Read Article
Saliclick: minor salivary gland biopsy was a safe and rapid procedure for the diagnosis in Sjögren’s Syndrome without observed numbness occurring, focal lymphocytic sialadenitis in 20%, with a focus score >1 for 62%. Hugle T, Abst#2190 #ACR23 @RheumNow https://t.co/VYKdQw2YlC https://t.co/dWLWj2AdkI
Dr. Antoni Chan ( View Tweet )
L18 @ #ACR23
⭐️Clinical Implications in Primary Sjögren's Syndrome (pSS) by Molecular classification of Salivary Glands (SGs)
➡️ transcriptomic profiling of SGs in Chinese cohort
👉 396 pSS, 87 non-pSS, & 44 early-pSS
➡️ 3 distinct sub-types:
⭐️Pacui-immune/C1… https://t.co/3ZdrghCB6F https://t.co/hZ9S3hvCzv
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
#ACR23 Late-Breaking Abstr#L10 Phase 2 crossover RCT of Dazodalibep, in #Sjogren pts with low ESSDAI but high ESSPRI. ESSPRI and FACIT-FATIGUE improved in both Stage 1 and also after X-over after 159 days. One to look out for those with high symptoms burden @RheumNow #ACRBest https://t.co/yGGrPmUOHU
Md Yuzaiful Md Yusof ( View Tweet )
#ACRbest Abstracts – Day 3
Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)
Read Article
Late breaking at #ACR23:
extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms
Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3!
ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85
David Liew @drdavidliew( View Tweet )
#ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP
Md Yuzaiful Md Yusof ( View Tweet )
#ACR23 Abstr#1636 Phase 2 crossover RCT of Dazodalibep, Anti-CD40L-i in #Sjogren pts with high disease activity showed primary endpoint, change in ESSDAI was met in DAZ vs PBO. More COVID in DAZ in Stage 1 but trial was at the start of pandemic. Phase 3 is starting soon @RheumNow https://t.co/hZcpOHumB3
Md Yuzaiful Md Yusof ( View Tweet )
#ACR23 Abstr#1634 Promising therapy for two #Sjogren groups: 1 (high ESSDAI & ESSPRI) & 2 (low ESSDAI, high ESSPRI). Phase 2 RCT of Iscalimab (anti-CD40ab) showed more ISC-treated pts met the primary endpoint (ESSDAI and ESSPRI changes at WK24) vs PBO. Going to Phase 3 @RheumNow https://t.co/3bN3IS1zCO
Md Yuzaiful Md Yusof ( View Tweet )
#ACR23 Abstr#0509 Is sero-ve #Sjogren sero-ve? A study showed promising diagnostic model comprises clinical & novel autoantibodies (DTD2) using whole peptidome array (AUC:74%) to avoid need for lips biopsy in ANA-ve. Need further validation & wider access to this test @RheumNow https://t.co/FmE8AJdMVe
Md Yuzaiful Md Yusof ( View Tweet )
You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest @ACRheum @RheumNow Pos#L10 https://t.co/DfChrAyslL
Janet Pope ( View Tweet )
#ACR23 Abstr#PP12 "I am stronger than my disease & won’t let it stop me from leading a fulfilling life!"- a person with #Sjogren shared tips on lifestyle modification to help fatigue.
- schedule appointments in the morning
- exercise
- keep a diary
- listen to body
@RheumNow https://t.co/8ROFrDvPS1
Md Yuzaiful Md Yusof ( View Tweet )
